spacer
home > epc > autumn 2002 > editor's letter
PUBLICATIONS
European Pharmaceutical Contractor

Editor's Letter

Traditionally, the drug industry has been immune to the vagaries of international stock market fluctuations. As I write this letter this immunity is beginning to be removed with 'scandals' depressing share values in both medium-sized companies such as Galen and Elan as well as the 'bellweather' giants such as Merck. That tradition should be usurped in this way is not good news for the CRO industry, any more than it is good news for the companies' shareholders. Pharma companies have always been conservative, even if their science was innovative. Stock price uncertainty will surely breed more conservatism and a reluctance to conduct research out-of-house, lest the company lose control. In just the same way as mega mergers put projects on hold or at risk, so the falling stock prices will tend to have the same effect.


But mega mergers of the type just announced between Pfizer and Pharmacia may not be the way to go. Productivity and efficiency no longer seem to be necessarily related to size, big organisations may become inefficient, if not impossible, to manage. This theme is developed by John Morris of KPMG who believes that there is likely to be a slow down in M&A activity in the near future.


However, M&A is seen as a way of achieving the holy grail of global reach not only in development but also in sales. Ben Coppin at Envisional discusses combined Internet sales and promotion of prescription products as a globalisation route. Although, as he points out, this may only be an acceptable practice if the Internet is somewhat regulated - how this is to be done will remain a challenge.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Graham Hughes
spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) a subsidiary of WuXi AppTec and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement